24/7 Market News Snapshot 28 January, 2025 – NLS Pharmaceutics Ltd. Ordinary Shares (NASDAQ:NLSP)

January 28, 2025

DENVER, Colo., 28 January, 2025 (247marketnews.com) – (NASDAQ:NLSP) are discussed in this article.
NLS Pharmaceutics Ltd. has reported a significant rise in its stock performance, opening at $1.83 and climbing to $1.945, reflecting a noteworthy gain of 7.46% from the previous close of $1.81. The heightened trading activity is characterized by a volume of 5.35 million shares, indicating strong investor interest and a potentially positive market sentiment surrounding the company’s pharmaceutical offerings. Investors are advised to keep a close watch on this trend, as sustained trading volume and price increases may signal further potential for growth in the near future.

In a strategic move, NLS Pharmaceutics has launched a preclinical program to investigate Mazindol ER (Extended-Release) as a treatment option for fentanyl dependence—a response to the growing opioid crisis. According to the Centers for Disease Control and Prevention (CDC), recent statistics revealed over 105,000 drug overdose deaths, with approximately 90% attributable to synthetic opioids such as fentanyl.

Alex Zwyer, the CEO of NLS Pharmaceutics, emphasized the urgent need for new treatment options amidst the escalating opioid epidemic. He highlighted Mazindol’s unique pharmacological properties, which may address various neurotransmitter systems involved in addiction. The company is optimistic that the upcoming preclinical studies will lead to innovative therapeutic solutions targeting both the physical and psychological aspects of opioid withdrawal.

The distinctive effectiveness of Mazindol rests on its modulation of critical neurotransmitter pathways. Research indicates that it can enhance mood and reduce anxiety through 5-HT1A receptor modulation, mitigate cravings by interacting with mu-opioid receptors, and partially activate orexin-2 receptors to improve disrupted sleep patterns during withdrawal.

With strong patent protections in place, NLS Pharmaceutics is dedicated to a thorough research and development process over the next 12 to 18 months, aiming to translate this promising data into viable clinical applications. The insights from this study not only aspire to enhance the understanding of Mazindol’s potential but also to set the groundwork for broader research initiatives in opioid dependence treatments.

Related news for (NLSP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.